Articles related to DEVICE/DRUG APPROVALS

The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.

Zevtera® (ceftobiprole medocaril) provides a significant advancement in treating serious bacterial infections, demonstrating high efficacy against both MRSA and MSSA in recent phase 3 clinical trials.

Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.